Pharmacare & Pharmaceutical Reform

We support reforms which will allow all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.

BMC Positions:
Submission to the Standing Committee on Health: Bill C-64, An Act Respecting Pharmacare (April 15, 2024) (Français)

Submission to Finance Canada: Priorities for the 2024-25 Federal Budget (February 8, 2024)

Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Pharmacare Position Points (September 2019)

Principles & Considerations Regarding Pharmacare (2016)

Submission: Standing Committee on Health (October 18, 2017)

CADTH Advisory Panel:
BMC Submission on Potential Pan-Canadian Formulary (February 25, 2022)

National Strategy for Drugs for Rare Diseases:
Op-ed: Canada must act to fund drugs for rare diseases (Ottawa Citizen, March 9, 2023)

BMC’s Submission on the National Strategy for Drugs for Rare Diseases — Additional Considerations (August 15, 2022)

BMC’s Submission on the National Strategy for Drugs for Rare Diseases (March 26, 2021)

Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations (July 2019)

Statement Regarding National Pharmacare Interim Report Announcement (March 6, 2019)

Positions and Considerations Regarding National Pharmacare Funding Options (January 2019)

National Pharmacare Implementation: Patient Perspectives and Considerations (September 2018)

BMC Survey:
Patient Perspectives on National Pharmacare: Current Challenges, Goals and Implementation Issues (August 2018)

Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (June 2018) (Français)

Go to the top